Evaxion arrives at its third-quarter report with its scientific story arguably in the best shape it has been in, and its balance sheet in some of the worst. That tension defines the November 19 release. Management spent the last call pointing to a firm date for three-year EVX01 melanoma data at ESMO in October, a new glioblastoma program, and a positive Phase 3 result from Moderna and Merck that it framed as validation for the entire personalized cancer vaccine field. The stock has not bought it. Shares are down about 16% since that report, trailing the S&P 500 by nearly 14 percentage points, and at $2.86 they sit well below the 200-day moving average of $3.45 and only modestly above the post-earnings low of $2.67.
The usual earnings yardsticks offer little here. Evaxion is a clinical-stage company without recurring product revenue, and there is no meaningful consensus figure or management guidance to anchor the quarter. The year-ago period showed a profit of $0.73 a share on $7.5 million of revenue, a comparison that will look unflattering against a company that lost $0.50 a share last quarter on a net loss of roughly $3.7 million. That gap is less a sign of deterioration than a reminder that Evaxion's income statement swings on deal economics. Without a signed partnership, the quarter should look much like the last two, with losses in the high three-million range.
What matters instead is cash. Evaxion ended the prior quarter with $14 million, down from $18.4 million a quarter earlier and $23 million at the end of fiscal 2025, a burn of about $4 million a quarter. Simple arithmetic points to something near $10 million before any capital raised. The wild card is the at-the-market facility, which management began tapping the day of the last call. A larger-than-expected cash balance would likely mean meaningful ATM issuance, which helps explain some of the share-price pressure. Management has reaffirmed a runway into the second half of 2027 on four consecutive calls without ever extending it. Holding that line again is the minimum; a credible extension, especially one not built mainly on dilution, would be a genuine positive.
The narrative test is whether the clinical momentum is turning into commercial traction. This will be the first report since the ESMO presentation, giving management a chance to explain how the three-year EVX01 durability data built on the earlier 75% response rate and 92% of responders still in response at two years. Durable follow-up, presented against the backdrop of a positive Phase 3 from larger rivals, is exactly the kind of evidence a pharma partner would want. Management said partnership conversations were accelerating, yet discussions have been described as ongoing since the third quarter of fiscal 2025, and the CEO declined to characterize deal stage last time. The lingering memory of MSD declining its gonorrhea vaccine option makes concrete progress more valuable than upbeat language. Updates on lead selection for the EVX05 glioblastoma vaccine with Duke would add color, but they will not move the needle the way a deal would.
Sentiment has swung sharply. Retail readings moved from mildly bearish ahead of the last report to strongly bullish now, even as the stock slid. That divergence suggests optimism is rooted in the ESMO catalyst and partnership hopes rather than in price action, which raises the risk of disappointment if management again offers only encouragement.
Ultimately, the report comes down to whether Evaxion can show that improved science is translating into financial staying power. A signed or clearly advancing oncology partnership, or a runway extension that does not rely heavily on the ATM, would validate last quarter's more confident tone. Another quarter of shrinking cash, open-ended deal talk and reliance on share sales would leave the stock's discount to its scientific narrative looking justified.